Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Cited by (1,049)

Items 401–500 of 1,049

1. Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: A meta-analysis of randomized controlled trials
   Nigel I. Kennedy, Won Hee Lee, Sophia Frangou · 2018 · European Psychiatry
2. CATIE and CUtLASS: can we handle the truth?
   Shôn W. Lewis, Jeffrey Alan Lieberman · 2008 · The British Journal of Psychiatry
3. A review of the association between antipsychotic use and hyperprolactinaemia
   Chris Bushe, Michael Shaw, Robert Peveler · 2008 · Journal of Psychopharmacology
4. Effects of typical and atypical antipsychotics on glucose–insulin homeostasis and lipid metabolism in first-episode schizophrenia
   Renrong Wu, Jingping Zhao, Zhening Liu, Jinguo Zhai, Xiaofeng Guo, Wenbing Guo, Jingsong Tang · 2006 · Psychopharmacology
5. Management of Neuropsychiatric Symptoms in People with Dementia
   Ballard, Clive, Corbett, Anne · 2010 · CNS Drugs
6. From Admission to Death: Prevalence and Course of Pain, Agitation, and Shortness of Breath, and Treatment of These Symptoms in Nursing Home Residents With Dementia
   Simone A. Hendriks, Martin Smalbrugge, Francisca Galindo‐Garre, Cees M.P.M. Hertogh, Jenny Theodora van der Steen · 2015 · Journal of the American Medical Directors Association
7. Current electroconvulsive therapy practice and research in the geriatric population
   Kerner, Nancy, Prudic, Joan · 2014 · Neuropsychiatry
8. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
   Henry A. Nasrallah, Robert Silva, Debra Phillips, Josephine B. Cucchiaro, Jay Hsu, Jane Xu, Antony D Loebel · 2013 · Journal of Psychiatric Research
9. Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder
   Jarskog, L. Fredrik, Hamer, Robert M., Catellier, Diane J., Stewart, Dawn D., LaVange, Lisa, Ray, Neepa, Golden, Lauren H., Lieberman, Jeffrey A., Stroup, T. Scott, for the METS Investigators · 2013 · American Journal of Psychiatry
10. A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder: A Canadian Network for Mood and Anxiety Treatments (CANMAT) Study
    Parikh, Sagar V., Zaretsky, Ari, Beaulieu, Serge, Yatham, Lakshmi N., Young, L. Trevor, Patelis-Siotis, Irene, MacQueen, Glenda M., Levitt, Anthony, Arenovich, Tamara, Cervantes, Pablo et al. · 2012 · The Journal of Clinical Psychiatry
11. A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia
    Timothy G. Calton, Michael Ferriter, Nick Huband, Helen Spandler · 2007 · Schizophrenia Bulletin
12. Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
    Rodrigo D. Paz, Sonia Tardito, Marco Atzori, Kuei Yuan Tseng · 2008 · European Neuropsychopharmacology
13. Acceptance- and mindfulness-based interventions for persons with psychosis: A systematic review and meta-analysis.
    Jansen, Jens Einar, Gleeson, John, Bendall, Sarah, Rice, Simon, Alvarez-Jimenez, Mario · 2020 · Schizophrenia Research
14. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
    Joseph J. Jankovic, Kathleen Clarence‐Smith · 2011 · Expert Review of Neurotherapeutics
15. Multifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy
    Shawn M. McClintock, Jimmy Choi, Zhi‐De Deng, Lawrence G. Appelbaum, Andrew D. Krystal, Sarah Hollingsworth Lisanby · 2014 · Journal of Ect
16. Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis
    Patrick D. McGorry, Barnaby Nelson, Lisa Phillips, Hok Pan Yuen, Shona M. Francey, Annette Thampi, Gregor Emanuel Berger, G. Paul Amminger, Magenta Bender Simmons, Daniel Kelly et al. · 2012 · The Journal of Clinical Psychiatry
17. Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study
    Ana Szarfman, Joseph M. Tonning, Jonathan G. Levine, Pudugramam Murali Doraiswamy · 2006 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
18. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions
    Pieter Roberto Bakker, Peter N. van Harten, Jim van Os · 2008 · Molecular Psychiatry
19. Drug models of schizophrenia
    Hannah Steeds, Robin Lester Carhart-Harris, James M. Stone · 2014 · Therapeutic Advances in Psychopharmacology
20. Understanding and Preventing Criminal Recidivism Among Adults With Psychotic Disorders
    J. Steven Lamberti · 2007 · Psychiatric Services
21. Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia: A Randomized, 1-Year Study
    Guo, Xiaofeng, Zhai, Jinguo, Liu, Zhening, Fang, Maosheng, Wang, Bo, Wang, Chuanyue, Hu, Bin, Sun, Xueli, Lv, Luxian, Lu, Zheng et al. · 2010 · Archives of General Psychiatry
22. Diabetes and Mental Health
    David J. Robinson, Meera Luthra, Michael Vallis · 2013 · Canadian Journal of Diabetes
23. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality
    Clive G. Ballard, Byron Creese, Anne Corbett, Dag Aarsland · 2010 · Expert Opinion on Drug Safety
24. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)
    Olivares, J.M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., Lam, A. · 2009 · European Psychiatry
25. Lurasidone: a new drug in development for schizophrenia
    Jonathan M. Meyer, Antony D Loebel, Edward Ernest Schweizer · 2009 · Expert Opinion on Investigational Drugs
26. Role of Dopamine D2 Receptors for Antipsychotic Activity
    Nathalie Ginovart, Shitij Kapur · 2012 · Handbook of experimental pharmacology
27. Results of phase 3 of the CATIE schizophrenia trial
    T. Scott Stroup, Jeffrey Alan Lieberman, Joseph P. McEvoy, Sonia Thomas, Marvin S. Swartz, Richard S.E. Keefe, Alexander L. Miller, Robert Alan Rosenheck, John Hsiao · 2008 · Schizophrenia Research
28. Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
    Miranda Chakos, Ira D. Glick, Alexander L. Miller, Mark B. Hamner, Del D. Miller, J. K. Patel, Andre M. Tapp, Richard S.E. Keefe, Robert Alan Rosenheck · 2006 · Psychiatric Services
29. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation
    Joel G Winner, Joseph M. Carhart, C. Anthony Altar, Seth Goldfarb, Josiah D. Allen, Gabriela Lavezzari, Kelly K. Parsons, Andrew G. Marshak, Susan B. Garavaglia, Bryan M. DeChairo · 2015 · Current Medical Research and Opinion
30. Genetics of Antipsychotic Treatment Emergent Weight Gain in Schizophrenia
    Daniel J. Müller, James L. Kennedy · 2006 · Pharmacogenomics
31. Drug-Induced Extrapyramidal Syndromes
    Stanley N. Caroff, E. Cabrina Campbell · 2016 · Psychiatric Clinics of North America
32. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis
    Mészáros, Ágnes, Czobor, Pál, Bálint, Sára, Komlósi, Sarolta, Simon, Viktória, Bitter, István · 2009 · The International Journal of Neuropsychopharmacology
33. Collaborative care for bipolar disorder, Part I: intervention and implementation in a randomized effectiveness trial.
    Bauer, Mark S., McBride, Linda, Williford, William O., Glick, Henry, Kinosian, Bruce, Altshuler, Lori, Beresford, Thomas, Kilbourne, Amy M., Sajatovic, Martha · 2006 · Psychiatric Services
34. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
    Rune A. Kroken, Erik Johnsen, Torleif Ruud, Tore Wentzel‐Larsen, Hugo Arild Jørgensen · 2009 · BMC Psychiatry
35. Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail
    Carla Vitorino, João Almeida, Lídia Gonçalves, António José Almeida, João Sousa, Alberto A. C. C. Pais · 2013 · Journal of Controlled Release
36. Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review
    Livia De Picker, Manuel Morrens, Steven Andrew Chance, Delphine Boche · 2017 · Frontiers in Psychiatry
37. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial
    Trino Baptista, Nairy Rangel, Virginia Fernández, Edgardo Carrizo, Yamily El Fakih, Euderruh Uzcátegui, Tatiana Galeazzi, M.A. Moriñigo Gutiérrez, Mercedes Servigna, Adriana Dávila et al. · 2007 · Schizophrenia Research
38. The case for long‐acting antipsychotic agents in the post‐CATIE era
    Henry A. Nasrallah · 2007 · Acta Psychiatrica Scandinavica
39. Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management
    Nancy Scotto Rosato, Christoph Ulrich Correll, Elizabeth A. Pappadopulos, Alanna Chait, Stephen Crystal, Peter S. Jensen · 2012 · PEDIATRICS
40. Remission and Relapse in the Outpatient Care of Schizophrenia
    Josep Maria Haro, Diego Novick, David L. Suarez, Jordi Alonso, Jean Pierre Lepine, Mark Ratcliffe · 2006 · Journal of Clinical Psychopharmacology
41. Medication adherence in patients with schizophrenia
    Stephanie V. Phan · 2016 · The International Journal of Psychiatry in Medicine
42. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode
    Dolores Keating, Stephen McWilliams, Ian Schneider, Caroline Hynes, Gráinne Cousins, Judith Strawbridge, Mary Clarke · 2017 · BMJ Open
43. Cardiometabolic effects of psychotropic medications
    Oluchi J. Abosi, Sneha Lopes, Samantha L. Schmitz, Jess G. Fiedorowicz · 2018 · Hormone Molecular Biology and Clinical Investigation
44. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.
    Vermeulen, J., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M., de Haan, L. · 2017 · Psychological Medicine
45. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
    Dold, Markus, Aigner, Martin, Lanzenberger, Rupert, Kasper, Siegfried · 2015 · International Journal of Neuropsychopharmacology
46. Specialty Care Medical Homes For People With Severe, Persistent Mental Disorders
    Vidhya Alakeson, Richard G. Frank, Ruth E. Katz · 2010 · Health Affairs
47. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
    James Maksymetz, Sean P. Moran, Peter Jeffrey Conn · 2017 · Molecular Brain
48. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study
    Diego Novick, Josep Maria Haro, David L. Suarez, Eduard Vieta, Dieter Naber · 2008 · Schizophrenia Research
49. Molecular pathophysiology of metabolic effects of antipsychotic medications
    Jacob S. Ballon, Utpal B. Pajvani, Zachary Freyberg, Rudolph L. Leibel, Jeffrey Alan Lieberman · 2014 · Trends in Endocrinology and Metabolism
50. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans
    Joanna Caroline Neill, Michael Harte, Peter Michael Haddad, Emma S. Lydall, Dominic Michael Dwyer · 2013 · European Neuropsychopharmacology
51. Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
    Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, John Michael Kane, Christoph Ulrich Correll · 2019 · World Psychiatry
52. Side Effects of Atypical Antipsychotics: Extrapyramidal Symptoms and the Metabolic Syndrome
    Arshia A. Shirzadi, S. Nassir Ghaemi · 2006 · Harvard Review of Psychiatry
53. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis
    Jeppesen, Rose, Christensen, Rune H.B., Pedersen, Emilie M.J., Nordentoft, Merete, Hjorthøj, Carsten, Köhler-Forsberg, Ole, Benros, Michael E. · 2020 · Brain, Behavior, and Immunity
54. Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders
    Millan, Mark J., Goodwin, Guy M., Meyer-Lindenberg, Andreas, Ove Ögren, Sven · 2015 · European Neuropsychopharmacology
55. A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: A five-year follow-up
    Douglas Turkington, Tom Sensky, Jan L. Scott, Thomas R. E. Barnes, Ula Nur, Ronald Siddle, Katherine Hammond, Neshika Samarasekara, David Kingdon · 2007 · Schizophrenia Research
56. Management of Antipsychotic-Induced Weight Gain: Prospective Naturalistic Study of the Effectiveness of a Supervised Exercise Programme
    Marie-Josée Poulin, Jean‐Philippe Chaput, Véronique Simard, Pierre Vincent, Joëlle Bernier, Yvan Gauthier, Guy Lanctôt, Jacynthe Saindon, Annick Vincent, Solange Gagnon et al. · 2007 · Australian & New Zealand Journal of Psychiatry
57. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size.
    Elizabeth A. Pappadopulos, Sophie Woolston, Alanna Chait, Matthew B. Perkins, Daniel F. Connor, Peter S. Jensen · 2006 · PubMed Central
58. Management of antipsychotic-related weight gain
    Lawrence A. Maayan, Christoph Ulrich Correll · 2010 · Expert Review of Neurotherapeutics
59. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research
    Jasmin Grigg, Roisin Worsley, Caroline Thew, Caroline Gurvich, Natalie Thomas, Jayashri Kulkarni · 2017 · Psychopharmacology
60. Dying Too Soon: Excess Mortality in Severe Mental Illness
    Liselotte D. de Mooij, Martijn Kikkert, Jan Theunissen, Aartjan T.F. Beekman, Lieuwe de Haan, Pim W. R. A. Duurkoop, Henricus L. Van, Jack Dekker · 2019 · Frontiers in Psychiatry
61. Cognitive Behavioral Therapy for Schizophrenia
    Shanaya Rathod, Peter Phiri, David Kingdon · 2010 · Psychiatric Clinics of North America
62. The Catatonia Conundrum: Evidence of Psychomotor Phenomena as a Symptom Dimension in Psychotic Disorders
    Gabor Sandor Ungvari, Stanley N. Caroff, József Gerevich · 2009 · Schizophrenia Bulletin
63. Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model
    Felipe V. Gomes, Millie Rincón‐Cortés, Anthony A. Grace · 2016 · Neuroscience & Biobehavioral Reviews
64. Current findings and perspectives on aberrant neural oscillations in schizophrenia
    Yoji Hirano, Peter J. Uhlhaas · 2021 · Psychiatry and Clinical Neurosciences
65. A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine
    John W. Newcomer, João Alberto de Oliveira Campos, Ronald N. Marcus, Christopher D. Breder, Robert Berman, Wendy Kerselaers, Gilbert J L'Italien, Marleen Nys, William H. Carson, Robert D. McQuade · 2008 · The Journal of Clinical Psychiatry
66. Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
    Martin Rhys Farlow, Michael L. Miller, Vojislav Pejović · 2008 · Dementia and Geriatric Cognitive Disorders
67. Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects
    Åberg, Karolina, Adkins, Daniel E., Bukszár, József, Webb, Bradley T., Caroff, Stanley N., Miller, Del D., Sebat, Jonathan, Stroup, Scott, Fanous, Ayman H., Vladimirov, Vladimir I. et al. · 2010 · Biological Psychiatry
68. Adjunctive psychosocial therapies for the treatment of schizophrenia
    Thomas L. Patterson, Oscar R Leeuwenkamp · 2008 · Schizophrenia Research
69. The Long-Term Effects of Conventional and Atypical Antipsychotics in Patients With Probable Alzheimer’s Disease
    Lopez, Oscar L., Becker, James T., Chang, Yue-Fang, Sweet, Robert A., Aizenstein, Howard, Snitz, Beth, Saxton, Judith, McDade, Eric, Kamboh, M. Ilyas, DeKosky, Steven T. et al. · 2013 · American Journal of Psychiatry
70. The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country
    Ulla A. Botha, Liezl Koen, John A. Joska, John Stanley Parker, Neil R. Horn, L Hering, Piet P. Oosthuizen · 2009 · Social Psychiatry and Psychiatric Epidemiology
71. Differential metabolic effects of antipsychotic treatments
    Dan W. Haupt · 2006 · European Neuropsychopharmacology
72. Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis
    Jeroen Koning, Diederik E. Tenback, Jim van Os, André Aleman, René S. Kahn, Peter N. van Harten · 2008 · Schizophrenia Bulletin
73. Effectiveness of Antipsychotic Drugs in Patients With Chronic Schizophrenia
    L. Kennedy · 2006 · Yearbook of Endocrinology
74. Serious Games, Gamification, and Serious Mental Illness: A Scoping Review
    Martin Fitzgerald, Gemma Ratcliffe · 2019 · Psychiatric Services
75. Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population
    Jean Bisimwa Nachega, Alice Jenh Hsu, Olalekan Abdulrahman Uthman, Anne Spinewine, Paul A. Pham · 2012 · AIDS
76. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
    Josep Maria Haro, David L. Suarez, Diego Novick, Jacqueline Brown, Judith Usall, Dieter Naber · 2006 · European Neuropsychopharmacology
77. The proteome of schizophrenia
    Juliana Minardi Nascimento, Daniel Martins‐de‐Souza · 2015 · Schizophrenia
78. Side effect burden of antipsychotic drugs in real life – Impact of gender and polypharmacy
    Trude Iversen, Nils Eiel Steen, Ingrid Dieset, Sigrun Hope, Ragni Helene Mørch, Erlend Strand Gardsjord, Kjetil Nordbø Jørgensen, Ingrid S. Melle, Ole A. Andreassen, Espen Molden et al. · 2017 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
79. Metacognitive Training for Schizophrenia Patients (MCT): A Pilot Study on Feasibility, Treatment Adherence, and Subjective Efficacy
    Steffen Moritz, Todd Stephen Woodward · 2014
80. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia
    McClay, Joseph L, Adkins, Daniel E, Åberg, Karolina, Bukszár, Jozsef, Khachane, Amit N, Keefe, Richard S E, Perkins, Diana O, McEvoy, Joseph P, Stroup, T Scott, Vann, Robert E et al. · 2011 · Neuropsychopharmacology
81. Untitled work
    2008 · PubMed
82. The Cost-Effectiveness of a Nonpharmacologic Intervention for Individuals With Dementia and Family Caregivers: The Tailored Activity Program
    Gitlin, Laura N., Hodgson, Nancy, Jutkowitz, Eric, Pizzi, Laura · 2010 · The American Journal of Geriatric Psychiatry
83. Exercise training for managing behavioral and psychological symptoms in people with dementia: A systematic review and meta-analysis
    Philipe de Souto Barreto, Laurent Demougeot, Fabien Pillard, Maryse Lapeyre‐Mestre, Yves Rolland · 2015 · Ageing Research Reviews
84. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia
    Jaime M. Monti, Pablo Torterolo, Seithikurippu Ratnas Pandi-Perumal · 2016 · Sleep Medicine Reviews
85. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
    Christoph Ulrich Correll, John W. Newcomer, Bernard L. Silverman, Lauren DiPetrillo, Christine E. Graham, Ying Jiang, Yangchun Du, Adam Simmons, Craig Hopkinson, David McDonnell et al. · 2020 · American Journal of Psychiatry
86. The CATIE Schizophrenia Trial: Results, Impact, Controversy
    Theo C. Manschreck, Roger A. Boshes · 2007 · Harvard Review of Psychiatry
87. Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)
    Strom, Brian L., Eng, Sybil M., Faich, Gerald, Reynolds, Robert F., D'Agostino, Ralph B., Ruskin, Jeremy, Kane, John M. · 2011 · American Journal of Psychiatry
88. History of Psychopharmacology
    Braslow, Joel T., Marder, Stephen R. · 2019 · Annual Review of Clinical Psychology
89. Melatonin attenuates antipsychotic metabolic effects: an eight‐week randomized, double‐blind, parallel‐group, placebo‐controlled clinical trial
    Francisco Romo‐Nava, Dení Álvarez-Icaza, Ana Fresán, Ricardo Arturo Saracco-Álvarez, Claudia Becerra‐Palars, Julia Moreno, Martha Patricia Ontiveros Uribe, Carlos Berlanga, Gerhard Heinze, Ruud M. Buijs · 2014 · Bipolar Disorders
90. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach
    Douglas M. Ruderfer, Alexander W. Charney, Ben Readhead, Brian A. Kidd, Anna K. Kähler, Paul J. Kenny, Michael J. Keiser, Jennifer L. Moran, Christina M. Hultman, Stuart Alexander Scott et al. · 2016 · The Lancet Psychiatry
91. Comparing Retrospective Reports to Real-Time/Real-Place Mobile Assessments in Individuals With Schizophrenia and a Nonclinical Comparison Group
    Dror Ben‐Zeev, Gregory J. McHugo, Haiyi Xie, Katharine Dobbins, Michael A. Young · 2012 · Schizophrenia Bulletin
92. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population
    Rocío Pérez‐Iglesias, Benedicto Crespo‐Facorro, Obdulia Martínez‐García, María Luz Ramírez-Bonilla, Mario Álvarez‐Jiménez, José María Pelayo‐Terán, María Teresa García‐Unzueta, José Amado, José Luis Vázquez‐Barquero · 2007 · Schizophrenia Research
93. Second-Generation Antipsychotics in Primary and Secondary Delusional Parasitosis
    Roland W. Freudenmann, Peter Lepping · 2008 · Journal of Clinical Psychopharmacology
94. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
    Amanda Krogmann, Luisa Peters, Laura von Hardenberg, Katja Bödeker, Viktor Benjamin Nöhles, Christoph Ulrich Correll · 2019 · CNS Spectrums
95. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
    Nigel Fleeman, Yenal Dundar, Rumona Dickson, Andrea Jorgensen, Sudeep P. Pushpakom, C McLeod, Munir Pirmohamed, T Walley · 2010 · The Pharmacogenomics Journal
96. Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients
    Christoph Ulrich Correll, Benjamin G. Druss, Ilise Lombardo, Cedric O’Gorman, James Harnett, Kafi N. Sanders, Jose M. Alvir, Brian J. Cuffel · 2010 · Psychiatric Services
97. Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis
    Roberts, Emmert, Eden Evins, A., McNeill, Ann, Robson, Debbie · 2016 · Addiction
98. DAI-10 is as good as DAI-30 in schizophrenia
    René Ernst Nielsen, Eva Lindström, Jimmi Nielsen, Sten E. Levander · 2012 · European Neuropsychopharmacology
99. Symptomatic Treatment of Huntington Disease
    Octavian R. Adam, Joseph J. Jankovic · 2008 · Neurotherapeutics
100. Schizophrenia: New Pathological Insights and Therapies
     L. Fredrik Jarskog, Seiya Miyamoto, Jeffrey Alan Lieberman · 2007 · Annual Review of Medicine